bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗

December 12, 2021

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...

Via Benzinga

New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels

December 11, 2021

From bluebird bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 22, 2021

Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's market cap stands at $44.9 million. Provention Bio (...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

November 22, 2021

Welcome back, traders! We're getting right into the week with a breakdown of the biggest pre-market stock movers for Monday!

Via InvestorPlace

Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA ↗

November 22, 2021

The FDA has accepted Bluebird bio Inc's (NASDAQ: BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has...

Via Benzinga

bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions

November 22, 2021

From bluebird bio, Inc.

Via Business Wire

64 Biggest Movers From Yesterday ↗

November 09, 2021

Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile...

Via Benzinga

Why Bluebird Bio Stock Plunged Today ↗

November 08, 2021

Two analysts downgraded the biotech stock.

Via The Motley Fool

Market Rally Continues as Dow Nabs Intraday Highs ↗

November 08, 2021

S&P 500 Index and Nasdaq Composite are sporting modest gains, with the Dow locking in another fresh intraday high.

Via Talk Markets

Topics Stocks

38 Stocks Moving In Monday's Mid-Day Session ↗

November 08, 2021

Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares climbed 129.8% to $7.49 after the company announced the launch of its E-Boost portfolio of mobile Electric Vehicle...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 08, 2021

Gainers PetVivo Holdings (NASDAQ:PETV) s...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 ↗

November 08, 2021

Upgrades For Nektar Therapeutics (NASDAQ:

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 05, 2021

Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. Trading volume for this security as of 12:30 EST is 1....

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 05, 2021

Gainers Ontrak (NASDAQ:OTRK) shares rose 21.82% to $11.78 during Friday's pre-market session. The market value of their outstanding shares is at $225.5 million. As per...

Via Benzinga

92 Biggest Movers From Friday ↗

November 08, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...

Via Benzinga

64 Stocks Moving In Friday's Mid-Day Session ↗

November 05, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the...

Via Benzinga

bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress

November 05, 2021

From bluebird bio, Inc.

Via Business Wire

bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row

November 05, 2021

From bluebird bio, Inc.

Via Business Wire

28 Stocks Moving in Friday's Pre-Market Session ↗

November 05, 2021

Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 65.8% to $2.14 in pre-market trading after the company announced its ReBoot device has been granted designation as a Breakthrough...

Via Benzinga

bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

November 04, 2021

From bluebird bio, Inc

Via Business Wire

bluebird bio Completes Planned Business Separation

November 04, 2021

From bluebird bio, Inc.

Via Business Wire

Bluebird Bio To Withdraw Marketing Of Skysona Gene Therapy In Europe ↗

October 21, 2021

Bluebird Bio Inc (NASDAQ: BLUE) will withdraw the regulatory marketing authorization for Skysona (elivaldogene autotemcel) in the European Union. The update comes...

Via Benzinga

Could This Beaten-Down Biotech Stock Be the Next Buyout Target? ↗

October 20, 2021

This gene-therapy specialist may need some help turning things around.

Via The Motley Fool

bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

October 18, 2021

From bluebird bio, Inc.

Via Business Wire

Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play? ↗

October 11, 2021

These once-promising biotech stocks are trading at a fraction of their all-time highs right now.

Via The Motley Fool

bluebird bio Provides Update on Upcoming Planned Business Separation

October 08, 2021

From bluebird bio, Inc.

Via Business Wire

Bluebird Bio Files US Application For β-thalassemia Gene Therapy ↗

September 22, 2021

Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel)...

Via Benzinga

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

September 21, 2021

From bluebird bio, Inc.

Via Business Wire

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗

September 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...

Via Benzinga

2seventy bio Announces Upcoming Investor Events

September 13, 2021

From bluebird bio

Via Business Wire

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.